ANGLE has completed a placing of new ordinary shares
ANGLE Plc has raised funds to develop the company.
ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.
Talk to the deal team
Ecorobotix has completed a fundraising
Ecorobotix has raised US$52 million. The new capital will enable the company to grow into new markets, expand its product range and build on the existing commercial success of ARA in Europe.Learn more
Presmed Australia has been acquired by ICG
Advanced Health Limited has sold Presmed Australia Pty Ltd (PMA) to ICG.Learn more
Pia Mater, a social services firm, has been acquired by SAT Heath
The founders of Pia Mater Ltd. have sold the company to SAT Health.Learn more